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Miltefosine is the most efficacious oral drug available for the treatment of leishmaniasis. While
miltefosine has been in use in India for the treatment of visceral leishmaniasis for a number of
years [1], its application to the treatment of cutaneous leishmaniasis is still under investigation
[2–4]. We recently reported that miltefosine was effective in the treatment of Leishmania ama-
zonensis infections in a mouse experimental model [5]. Those results were obtained in BALB/c
mice infected with two different L. amazonensis strains: a type strain (M2269) and an isolate
obtained from a patient with diffuse cutaneous leishmaniasis (2506). Five weeks after infection,
treatment was initiated when lesions on the hind left footpad were apparent. Miltefosine 13
mg/kg/day was given orally for 15 consecutive days to groups composed of five mice. The ani-
mals infected with M2269 or 2506 parasites were considered clinically cured at the end of treat-
ment. One week after the end of treatment, the mice were humanely killed for parasitological
examination. Histopathological examinations of the infection site and limiting dilution assays
performed with the footpad tissue revealed an absence of parasites [5]. Clinical follow-up for
15 weeks after the end of the treatment showed no signs of relapse. These results were consid-
ered as evidence that treatment with miltefosine in this murine model of cutaneous leishmania-
sis, a model of extreme susceptibility, was highly efficacious.
Subsequently, one of the groups described, consisting of four remaining mice infected with
the M2269 strain and treated with the same dose of miltefosine, was followed up for a longer
period. These animals relapsed from the 23rd week post-infection. Lesions became apparent in
all four mice and appeared individually in weeks 23, 36, 39, and 39 post-infection. At these
times, parasites were recovered from lesions, and the susceptibility to miltefosine was deter-
mined, as described by Coelho et al. [5]. No significant changes in drug susceptibility were
found, indicating that there was no acquired resistance to miltefosine during therapy.
Furthermore, we reported that the diffuse cutaneous leishmaniasis patient from which the
2506 strain had been isolated was responding well to miltefosine and pentamidine combined
therapy [5]. However, after 18 months the disease reoccurred, requiring a new course of treat-
ment. Previous clinical studies also described the occurrence of relapses after miltefosine che-
motherapy in patients with diffuse cutaneous leishmaniasis [6,7].
Parasite persistence after treatment with various drugs has been described [8–11] and may,
in fact, be the rule in leishmaniasis. The relapses observed in this group of mice indicate that
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the techniques used in our previous report to characterize the parasite burden (histopathology
and limiting dilution) lack the sensitivity to detect these remaining or quiescent parasites. We
believe these findings are significant to the data previously reported.
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